NCT01604772 · OUTCOME

Incidence of Toxicities of Akt Inhibitor MK-2206

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma · Source last updated 2019-05-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Time to first treatment to up to 30 days after completion of treatment

What was measured

Safety will be assessed in terms of the number of participants reporting grade 3 or higher adverse events as evaluated by Common Terminology Criteria for Adverse Events v4.0 (CTCAE).

Analysis population: All patients that started protocol treatment were included in this analysis.

Groups in this outcome

Treatment (Akt Inhibitor MK2206)

Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Akt Inhibitor MK2206: 150 mg given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Akt Inhibitor MK2206)	16

Reported measurements

Grade 3 Adverse Event

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Akt Inhibitor MK2206)	10	Not reported	Not reported	Not reported	Not reported

Grade 4 Adverse Event

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Akt Inhibitor MK2206)	2	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
10
title
Grade 3 Adverse Event
categories
measurements
group Id
OG000
value
2
title
Grade 4 Adverse Event

denoms

counts
group Id
OG000
value
16
units
Participants

description

Safety will be assessed in terms of the number of participants reporting grade 3 or higher adverse events as evaluated by Common Terminology Criteria for Adverse Events v4.0 (CTCAE).

groups

description
Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Akt Inhibitor MK2206: 150 mg given PO
id
OG000
title
Treatment (Akt Inhibitor MK2206)

param Type

COUNT_OF_PARTICIPANTS

population Description

All patients that started protocol treatment were included in this analysis.

reporting Status

POSTED

time Frame

Time to first treatment to up to 30 days after completion of treatment

title

Incidence of Toxicities of Akt Inhibitor MK-2206

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice